Reference SummaryBabar IA, Proc Natl Acad Sci U S A 2012 Jun 26;109(26):E1695-704
Title |
Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma. |
Authors |
Babar IA; Cheng CJ; Booth CJ; Liang X; Weidhaas JB; Saltzman WM; Slack FJ |
Journal |
Proc Natl Acad Sci U S A |
Volume |
109 |
Issue |
26 |
Year |
2012 |
Pages |
E1695-704 |
Abstract |
MicroRNA-155 (miR-155) is an oncogenic microRNA that regulates several pathways involved in cell division and immunoregulation. It is overexpressed in numerous cancers, is often correlated with poor prognosis, and is thus a key target for future therapies. In this work we show that overexpression of miR-155 in lymphoid tissues results in disseminated lymphoma characterized by a clonal, transplantable pre-B-cell population of neoplastic lymphocytes. Withdrawal of miR-155 in mice with established disease results in rapid regression of lymphadenopathy, in part because of apoptosis of the malignant lymphocytes, demonstrating that these tumors are dependent on miR-155 expression. We show that systemic delivery of antisense peptide nucleic acids encapsulated in unique polymer nanoparticles inhibits miR-155 and slows the growth of these \"addicted\" pre-B-cell tumors in vivo, suggesting a promising therapeutic option for lymphoma/leukemia. |
Links |
J:185598 – MGI References 22685206 – National Library of Medicine/PubMed |
| Strain | Model Name | Treatment Agent(s) | Organ Affected | Frequency | Model Details |
|---|---|---|---|---|---|
| B6;FVB-Gt(ROSA)26Sortm1(tTA,tetO-Mir155)Fjsl/Gt(ROSA)26Sor Tg(Nes-cre)1Wmz | CNS - Brain tumor |
|
CNS - Brain |
0 |
|
| B6;FVB-Gt(ROSA)26Sortm1(tTA,tetO-Mir155)Fjsl/Gt(ROSA)26Sor | CNS - Brain tumor |
|
CNS - Brain |
0 |
|
| B6;FVB-Gt(ROSA)26Sortm1(tTA,tetO-Mir155)Fjsl/Gt(ROSA)26Sor Tg(Nes-cre)1Wmz | Leukocyte - Lymphocyte - B-lymphocyte lymphoma |
|
Leukocyte - Lymphocyte - B-lymphocyte |
observed |
|
| B6;FVB | Leukocyte - Lymphocyte - B-lymphocyte lymphoma |
|
Leukocyte - Lymphocyte - B-lymphocyte |
0 |
|
| B6;FVB-Gt(ROSA)26Sortm1(tTA,tetO-Mir155)Fjsl/Gt(ROSA)26Sor Tg(Nes-cre)1Wmz | Liver hyperplasia |
|
Liver |
observed |
|
| B6;FVB-Gt(ROSA)26Sortm1(tTA,tetO-Mir155)Fjsl/Gt(ROSA)26Sor Tg(Nes-cre)1Wmz | Lymph node hyperplasia |
|
Lymph node |
0 - observed |
|
| B6;FVB | Lymph node hyperplasia | Lymph node |
0 |
||
| B6;FVB-Gt(ROSA)26Sortm1(tTA,tetO-Mir155)Fjsl/Gt(ROSA)26Sor Tg(Nes-cre)1Wmz | Spleen hyperplasia |
|
Spleen |
0 - observed |
|
| B6;FVB | Spleen hyperplasia | Spleen |
0 |
||
| B6;FVB-Gt(ROSA)26Sortm1(tTA,tetO-Mir155)Fjsl/Gt(ROSA)26Sor Tg(Nes-cre)1Wmz | Thymus hyperplasia |
|
Thymus |
observed |
|
| B6;FVB | Thymus hyperplasia | Thymus |
0 |